Hot Stocks: Twitter Inc (NYSE:TWTR), CGI Group (NYSE:GIB), Calix Inc (NYSE:CALX), Hemispherx BioPharma, Inc (NYSEMKT:HEB), CommVault Systems (NASDAQ:CVLT)

Twitter Inc (NYSE:TWTR), has announced that its international head of strategy, Katie Stanton, has now been appointed as head of global media operations, replacing Chloe Sladden as part of a wider management shakeup at the microblogging service. Twitter Inc (NYSE:TWTR), net profit margin is -93.70% and weekly performance is -8.69%. On last trading day company shares ended up $37.41. Analysts mean target price for the company is $43.84. Twitter Inc (NYSE:TWTR), distance from 50-day simple moving average (SMA50) is 3.72%.

CGI Group Inc. (USA) (NYSE:GIB), said it has been awarded a 10 year, multi-billion dollar contract by General Services Administration, under a new contract vehicle known as One Acquisition Solution for Integrated Services or OASIS. CGI Group Inc. (USA) (NYSE:GIB), fell 0.88% in last trading session and ended the day on $34.92. GIB, Gross Margin is 12.00% and its return on assets is 6.50%. CGI Group Inc. (USA) (NYSE:GIB), quarterly performance is 12.43%.

Calix Inc (NYSE:CALX), announced the addition of telecommunications industry veteran Christopher J. Bowick to the company’s Board of Directors, replacing Michael Ashby who served on the company’s board of directors and retired as the company’s CFO in February 2014. A seasoned executive with over 25 years of cable television industry experience, Bowick has held leadership positions at Cox Communications, Charter Communications, Jones Intercable, and Scientific-Atlanta. Calix Inc (NYSE:CALX), shares moved down 1.74% in last trading session and was closed at $7.89, while trading in range of $7.82 – 8.05. Calix Inc (NYSE:CALX), year to date (YTD) performance is -18.15%.

Hemispherx BioPharma, Inc (NYSEMKT:HEB), announced execution of an agreement to seek South African government approval to initiate a study of Alferon(R) N, the only FDA approved natural interferon, in the suppression of HIV Type 1 replication and the reduction/elimination of functional cell-associated HIV DNA integration (latent HIV). The study is contemplated as part of a broad strategic alliance with Bioclones (Pty) Ltd. (“Bioclones”), a leading South African biotechnology company. Hemispherx BioPharma, Inc (NYSEMKT:HEB), ended the last trading day at $0.295. Company weekly volatility is calculated as 6.71% and price to cash ratio as 2.57. Hemispherx BioPharma, Inc (NYSEMKT:HEB), showed a negative weekly performance of 3.23%.

Shares of CommVault Systems, Inc. (NASDAQ:CVLT), have been given a consensus rating of “Buy” by the sixteen analysts that are currently covering the company, American Banking & Market News reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $60.74. CommVault Systems, Inc. (NASDAQ:CVLT), net profit margin is 11.00% and weekly performance is -3.32%. On last trading day company shares ended up $47.54. Analysts mean target price for the company is $62.64. CommVault Systems, Inc. (NASDAQ:CVLT), distance from 50-day simple moving average (SMA50) is -3.28%.